Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine–Enhanced Liver Magnetic Resonance

Linda Chi Hang Chu, Chiara Pozzessere, Celia Corona Villalobos, Sandra Castaños, Neda Rastegar, Vivek Halappa, Susanne Bonekamp, Emi Emurano, Ihab R Kamel

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: Use of gadobenate dimeglumine–enhanced liver magnetic resonance (MR) for evaluation of hepatocellular carcinoma tumor response after transcatheter arterial chemoembolization (TACE). METHODS: Forty-five patients with hepatocellular carcinoma were imaged with multiphase gadobenate dimeglumine–enhanced MR examination at baseline and 1-month follow-up after TACE. Nodule size, enhancement, and apparent diffusion coefficient were measured for both examinations by 2 reviewers. Changes in tumor nodule size, enhancement, and apparent diffusion coefficient were evaluated using the Student t test. RESULTS: Nineteen of 45 patients completed the study, and a total of 34 hepatocellular carcinoma nodules were analyzed. On the posttreatment follow up, there was no significant change in nodule size. Target lesions demonstrated significant decrease in tumor enhancement after TACE (P < 0.001). Intense contrast accumulation along the periphery of the presumed necrotic tumor on the delayed hepatobiliary phase helped to differentiate viable from non-viable tumor. CONCLUSION: Gadobenate dimeglumine–enhanced liver MR may help differentiate between viable and necrotic tumor after TACE.

Original languageEnglish (US)
JournalJournal of Computer Assisted Tomography
DOIs
StateAccepted/In press - Sep 27 2016

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine–Enhanced Liver Magnetic Resonance'. Together they form a unique fingerprint.

Cite this